Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2024—Sebia announced it has received FDA 510(k) clearance for its Capillarys 3 DBS instrument. The capillary electrophoresis-based automated analyzer is intended for the detection of normal hemoglobins (F and A) and abnormal hemoglobins (S, C, E, D, and Barts) in blood collected on filter paper from newborns. The instrument can analyze up to eight 96-well microplates and has a throughput of 70 tests per hour.
June 2024—Verichem Laboratories now offers a liquid-stable, ready-to-use set of multilevel clinical reference materials for the calibration verification of ethanol assays. The company also offers two multilevel test kits of clinical reference materials for the calibration verification of lithium assays intended for use with direct and indirect ion selective electrodes, colorimetric assays, and flame photometers.
June 2024—Affinity Biosensors announced that its LifeScale AST system received FDA 510(k) clearance. The multiplex in vitro diagnostic test uses a microfluidic sensor and resonant frequency to calculate organism concentration and/or mass distribution for quantitative antimicrobial susceptibility testing. Testing is performed directly on blood cultures signaled as positive by a continuous monitoring blood culture system and confirmed by Gram stain. Results are available in less than five hours.
May 2024—Recordati Rare Diseases has introduced its new educational website, Think iMCD, at https://thinkimcd.us. The platform is tailored for pathologists and offers comprehensive support for the diagnostic process of idiopathic multicentric Castleman disease (iMCD). The website provides an overview of iMCD diagnostic criteria, practical steps for assessing lymph node biopsies, and links to additional resources for understanding CD/iMCD. Designed to enhance professional awareness and comprehension, the site aims to be a valuable tool for the medical community.
May 2024—Leica Biosystems has published “101 Steps to Better Histology—A Practical Guide to Good Histology Practice,” written by histology consultant Geoffrey Rolls. The guide provides practical advice on best-practice techniques and simple ways to avoid common errors and covers each aspect of the histology process: specimen collection, grossing, processing, embedding, and sectioning and staining. It is downloadable free of charge on Leica’s “Knowledge Pathway” site.
May 2024—Quantimetrix announced that its Dipper POCT urinalysis dipstick control pouches now include a barcode. The integrated barcode is designed to streamline the workflow and reduce errors that can arise from manually entering lot numbers and expiration dates. Dipper POCT kits contain ready-to-use, single-use plastic pouches in two levels, each filled with 1.5 mL of liquid control material. The product is stable for three months at room temperature and up to three years at 2º to 8ºC.
May 2024—Polymedco announced FDA 510(k) clearance of the Pathfast hs-cTnI-II, a high-sensitivity cardiac troponin assay for the diagnosis of myocardial infarction at the point of care. The test delivers results in 17 minutes on the Pathfast Biomarker analyzer using whole blood and plasma samples.
May 2024—PixCell Medical announced a strategic distribution partnership with Medline, Henry Schein, and Thermo Fisher Scientific to increase accessibility to its flagship product, the HemoScreen point-of-care, five-part differential CBC analyzer, in the United States. The FDA-cleared analyzer can be used with capillary or venous anticoagulated whole blood and provides results in five minutes.
May 2024—Bio-Rad Laboratories has launched its Unity Next Peer QC data management software in Europe, the Middle East, and Africa. The software is designed to help troubleshoot quality control failures and increase confidence in patient testing results and offers on-demand access to peer reporting and quality control data. Labs new to Bio-Rad’s suite of QC data management products can get guided support and training from the company.
May 2024—Sysmex America announced it will sell hemostasis instruments and reagents to laboratories in the United States under the company’s mutual original equipment manufacturer agreement with Siemens Healthineers. The agreement allows the companies to distribute hemostasis instruments provided by Sysmex and reagents provided by Siemens under their respective brands.
